Zenyatta Ventures Ltd Share Price Toronto S.E.
Equities
CA98943A1012
Biotechnology & Medical Research
Sales 2022 | 0.35 0.47 27.64 | Sales 2023 | 0.07 0.1 5.8 | Capitalization | 206M 282M 16.4B |
---|---|---|---|---|---|
Net income 2022 | -38M -51.93M -3.03B | Net income 2023 | -14M -19.13M -1.11B | EV / Sales 2022 | 1,031,593,065 x |
Net cash position 2022 | 24.44M 33.4M 1.95B | Net cash position 2023 | 8.75M 11.95M 696M | EV / Sales 2023 | 2,707,984,696 x |
P/E ratio 2022 |
-9.19
x | P/E ratio 2023 |
-14.3
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.07% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Fenton
CEO | Chief Executive Officer | - | 10/07/18 |
Wendy Ford
DFI | Director of Finance/CFO | - | 15/05/22 |
Adam MacIntosh
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ilse Treurnicht
BRD | Director/Board Member | - | 04/07/22 |
John Snisarenko
BRD | Director/Board Member | 61 | 04/10/23 |
Francis Dubé
COO | Chief Operating Officer | - | 10/05/18 |
1st Jan change | Capi. | |
---|---|---|
+1.46% | 42.75B | |
+47.70% | 41.61B | |
+12.10% | 41.34B | |
-8.83% | 26.59B | |
+6.96% | 25.49B | |
-23.03% | 18.12B | |
+29.96% | 12.24B | |
-2.31% | 11.76B | |
+8.37% | 11B |